Skip to main content
NCBI home page
Therapeutic Advances in Urology logoLink to Therapeutic Advances in Urology
. 2015 Oct;7(5):249–264. doi: 10.1177/1756287215589238

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

Osamu Yokoyama 1,✉, Yasuhiko Igawa 2, Masayuki Takeda 3, Takafumi Yamaguchi 4, Masahiro Murakami 5, Lars Viktrup 6
PMCID: PMC4549700  PMID: 26425140

Abstract

Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, is approved worldwide for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS). The purpose of this narrative review is to summarize the clinical data on tadalafil 5 mg once-daily, primarily focusing on Asian men with BPH-LUTS, and to update the current understanding of the mechanism of action underlying PDE5 inhibition. Findings from studies have demonstrated that PDE5 is highly expressed in the lower urinary tract and supporting vasculature, and that PDE5 inhibition potentially decreases smooth muscle cell proliferation in the prostate, relaxes smooth muscle in the prostate, bladder neck and supporting vasculature, increases blood perfusion to the lower urinary tract, and modulates bladder afferent nerve activity. A total of 11 larger, 12-week, double-blind, randomized, placebo-controlled studies of tadalafil, including four Asian studies, have been conducted globally, enrolling >3000 men with BPH-LUTS. In addition, two long-term (42- and 52-week) studies enrolled 394 Japanese and 428 North American men, respectively, with BPH-LUTS. Overall, tadalafil 5 mg once-daily resulted in significant improvements in the change from baseline to endpoint in total International Prostate Symptom Scores (IPSS), IPSS storage and voiding subscores, and IPSS quality of life index compared with placebo. Tadalafil was well tolerated and had a favorable safety profile. These findings support tadalafil 5 mg once-daily for treating men, including Asian men, with BPH-LUTS.

Keywords: Asia, benign prostatic hyperplasia, lower urinary tract symptoms, mechanism of action, tadalafil

Introduction

Benign prostatic hyperplasia (BPH) is a histological diagnosis characterized by nonmalignant hyperplasia of prostatic tissue that is caused by smooth muscle and epithelial cell proliferation in the prostate transition zone [Roehrborn, 2008; Oelke et al. 2013]. This hyperplasia results in prostate enlargement [Roehrborn, 2008; Oelke et al. 2013], which can in turn lead to the development of lower urinary tract symptoms (LUTS) such as storage, voiding and postmicturition symptoms [Abrams et al. 2003; Homma et al. 2011]. An increased smooth muscle tone in the prostate or the vasculature supporting the lower urinary tract may play a contributing role [Homma et al. 2011]. LUTS secondary to BPH (BPH-LUTS) are common in aging men worldwide [Verhamme et al. 2002; Irwin et al. 2006; Coyne et al. 2009], including Asia [Tsukamoto et al. 1995; Lee et al. 1998; Li et al. 2005; Kang et al. 2011]. In the US, approximately 75% of men aged 60–69 years and 83% of men aged 70 years or older are estimated to have BPH-LUTS [Wei et al. 2008]. In Japan, an estimated 1.98 million men were projected to require treatment for BPH-LUTS in 2010, a number that is expected to increase to 2.19 million by 2030 [Terai et al. 2000]. Given that BPH-LUTS often interferes with activities of daily living [Rosen et al. 2003], many men with BPH-LUTS seek treatment to improve their quality of life (QoL) [Jacobsen et al. 1993].

Pharmacological treatment for men with BPH-LUTS typically begins with an α-adrenergic blocker (α-blocker), with the addition of a 5-α-reductase inhibitor (5ARI) in men with verified prostate enlargement. Of these treatments, α-blockers may reduce LUTS within weeks, whereas 5ARIs have a slower onset of action (within 6–12 months) [Homma et al. 2011; Oelke et al. 2013]. Long-term treatment with 5ARIs may also reduce the risk of urinary retention and surgical intervention [American Urological Association Practice Guidelines Committee, 2010; Oelke et al. 2013]. Although these treatments may be effective, individually or in combination, some men do not respond or experience side effects such as sexual dysfunction, including ejaculatory disorders (α-blockers and 5ARIs), orthostatic hypotension (α-blockers) and intraoperative floppy iris syndrome during cataract surgery (α-blockers) [Homma et al. 2011]. Further, persistent adverse effects on sexual function, including erectile dysfunction (ED) and decreased libido, have been reported in a subset of patients with BPH-LUTS treated with 5ARIs [Traish et al. 2011].

Recently, the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, widely approved as once-daily and/or on-demand treatment for ED, has been approved (5 mg once-daily) for the treatment of BPH-LUTS worldwide, including in several Asian countries, the US and the European Union. Like α-blockers, tadalafil has an onset of action that occurs within weeks [Egerdie et al. 2012; Oelke et al. 2012; Yokoyama et al. 2013]. The efficacy of PDE5 inhibitors, with a focus on tadalafil clinical data, was acknowledged in the recent guidelines published by the Japanese Urological Association (JUA) [Homma et al. 2011] and the European Association of Urology (EAU) [Oelke et al. 2013], both of which state that there is Level 1 evidence (i.e. from multiple, large-scale, randomized, controlled trials, the majority involving tadalafil) supporting the efficacy of PDE5 inhibitors for the treatment of BPH-LUTS.

The purpose of this narrative review, focusing on Asian men with BPH-LUTS, is to summarize the clinical data on tadalafil 5 mg once-daily as monotherapy or in combination with α-blockers or 5ARIs, and to update the current understanding of the mechanism of action underlying PDE5 inhibition. The review of clinical data was focused on published findings from key randomized, placebo-controlled studies examining the efficacy of tadalafil 5 mg once-daily in men (n ⩾ 50 in the tadalafil treatment arm) with BPH-LUTS.

Potential pathology

Pathophysiological changes underlying the development of BPH-LUTS are multifaceted and may include reduced pelvic nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling, overactivity of the autonomic nervous system, atherosclerosis, pelvic ischemia, increased Rho-kinase activity (which mediates smooth muscle contraction by modulating the activity of myosin phosphatase), an altered androgen environment and tissue inflammation [Andersson et al. 2011]. These changes may mediate increased smooth muscle cell (SMC) proliferation, SMC tone and bladder afferent nerve activity [Andersson et al. 2011; Giuliano et al. 2013]. The resultant structural and functional changes in the bladder, prostate, supporting vasculature and nerve innervation can affect bladder function [Andersson et al. 2011]. Metabolic syndrome may be independently associated with BPH-LUTS [Moul and McVary, 2010]. Although a direct causal link has not been identified, several of the characteristic changes associated with metabolic syndrome, including insulin resistance, hormonal changes, pelvic atherosclerosis and inflammation, seem to contribute to the development of LUTS [De Nunzio et al. 2012]. The results of a recently published systematic review and meta-analysis have also demonstrated a link between metabolic syndrome, in particular dyslipidemia and central obesity, and prostate enlargement [Gacci et al. 2015].

Location of PDE5 isoenzymes

To date, PDE5 isoenzymes have been identified in the SMCs of the corpus cavernosum [Taher et al. 1997], vascular and visceral smooth muscle [Rybalkin et al. 1999; Watkins et al. 2000], skeletal muscle [Loughney et al. 1998], platelets [Haslam et al. 1999], kidney [Kotera et al. 2000], lung [Cortijo et al. 1998], spinal cord [Fullhase et al. 2013], cerebellum [Kotera et al. 2000] and pancreas [Loughney et al. 1998]. In the lower urinary tract, PDE5 isoenzymes have been identified in the prostate [Uckert et al. 2001; Filippi et al. 2007; Waldkirch et al. 2007; Fibbi et al. 2010; Morelli et al. 2011a], urethra [Werkstrom et al. 2006; Fibbi et al. 2010; Morelli et al. 2011a] and bladder [Filippi et al. 2007; Fibbi et al. 2010; Morelli et al. 2011a] (Figure 1).

Figure 1.

Figure 1.

Open in a new tab

Location of phosphodiesterase type 5 (PDE5) isoenzymes in the lower urinary tract.

Note: This figure was originally published in Eur Urol 2013; 63: 506–516.

PDE5 inhibition

In NO/cGMP signaling, PDE5 isoenzymes catalyze cGMP hydrolysis, thereby regulating the activity of cGMP-dependent protein kinases (PKGs) [Francis et al. 2010]. The proteins modified by PKGs play a role in regulating cellular calcium homeostasis [Francis et al. 2010]. The inhibition of PDE5 in SMCs potentiates the action of NO by increasing cGMP concentrations which, in turn, lead to calcium efflux and SMC relaxation. The inhibition of PDE5 isoenzymes in the lower urinary tract mediates a number of processes that may help relieve BPH-LUTS.

Smooth muscle relaxation

Organ bath studies of human prostate and bladder tissue have shown that PDE5 inhibitors induce smooth muscle relaxation. Specifically, a study of human prostate tissue, obtained from patients with BPH who underwent suprapubic adenectomy or from organ donors free from urologic disease, demonstrated that tadalafil potentiated sodium nitroprusside (SNP) induced relaxation in muscle strips and enhanced cGMP accumulation in homogenized tissue [Angulo et al. 2012]. Other studies demonstrated that PDE5 inhibitors attenuated α-adrenergic-induced contractions [Uckert et al. 2001; Uckert et al. 2008], including in a concentration-dependent manner [Uckert et al. 2008], or electrical field-induced contractions [Takeda et al. 1995] in isolated human prostate strips obtained from nonmalignant tissue from men who had undergone surgery for localized prostate or urinary bladder cancer. Studies have also demonstrated that vardenafil potentiated SNP-induced relaxation [Filippi et al. 2007],and that sildenafil citrate induced relaxation [Bittencourt et al. 2009], of precontracted human bladder neck strips obtained from men undergoing transvesical prostate adenectomy, radical cystectomy or radical prostatectomy.

Increased blood perfusion

Animal and human studies have shown that PDE5 inhibitors can increase prostate and/or bladder blood perfusion. In spontaneously hypertensive rats (SHR), which exhibit prostate hyperplasia, bladder overactivity, and an increased density of hypoxic cells in prostate and bladder tissue, 7 days of tadalafil administration normalized the density of hypoxic cells in prostate tissue slices [Morelli et al. 2011a]. Likewise, in a similar SHR study, vardenafil, administered 90 minutes before sacrifice, normalized the density of hypoxic cells in bladder tissue slices [Morelli et al. 2010]. In a clinical study, an increase in prostate microcirculation was demonstrated, using power Doppler ultrasound, 60 minutes after vardenafil 20 mg administration in men (n = 9) who were prostate biopsy naïve and had a prostate-specific antigen concentration >4 ng/ml at first diagnosis with negative digital rectal and transrectal ultrasound examinations [Morelli et al. 2011b]. In another study, an increase in prostate blood flow was demonstrated, using transrectal contrast-enhanced ultrasound, 90 minutes after tadalafil 20 mg administration in men (n = 12) with BPH awaiting benign prostate surgery [Bertolotto et al. 2009]. Furthermore, in a case report of a man with a normal prostate, an approximate 75% increase in prostate blood flow was detected using dynamic contrast enhanced magnetic resonance imaging 60 minutes after administration of sildenafil citrate 25 mg [Haaga et al. 2007].

Encouraged by these results, a double-blind, randomized, placebo-controlled study of 97 men with BPH-LUTS was carried out to assess the arterial resistive index in the prostate transition zone and other flow measures in the prostate peripheral zone and bladder neck via transrectal ultrasonography after 8 weeks of tadalafil 5 mg once-daily therapy compared with placebo [Pinggera et al. 2014]. However, no detectable improvements were observed across several parameters. One potential explanation for the lack of improvement is that the prostatic arterial resistive index observed at baseline was less severe than reported in previous studies [Kojima et al. 1997; Tsuru et al. 2002; Berger et al. 2005; Ozden et al. 2010; Abdelwahab et al. 2012; Zhang et al. 2012], leaving less room for improvement. Other explanations include potential insufficient sensitivity of the novel techniques used, methodological variability across study sites, or PDE5 inhibition having an inconsistent impact on prostate blood perfusion [Pinggera et al. 2014].

Inhibition of PDE5 may also affect vascular reactivity via mediators of endothelial function. Specifically, sildenafil citrate has been demonstrated to enhance epithelial NO synthase (eNOS) expression in the sickle cell mouse penis [Musicki et al. 2014] and to restore eNOS activation in human umbilical vein endothelial cells cultured under conditions designed to mimic insulin resistance [Mammi et al. 2011]. Moreover, a study of 32 men with increased cardiovascular risk demonstrated that 4 weeks of treatment with tadalafil 20 mg resulted in improved brachial artery flow-mediated dilation and decreased plasma concentrations of endothelin-1, a vasoconstrictor produced by the vascular endothelium [Rosano et al. 2005].

Decreased afferent nerve activity

Animal studies involving models of bladder distension, spinal cord injury and bladder outlet obstruction have shown that PDE5 inhibition modulates bladder afferent nerve activity. Specifically, tadalafil significantly decreased the single bladder afferent (afferents were identified by electrical stimulation of the pelvic nerve and bladder distension) activity of both Aδ- and C-fibers induced by bladder distension or acrolein instillation in rats [Minagawa et al. 2012]. In another study, vardenafil decreased both bladder afferent (afferents were identified as described above) nerve firing during filling and the amplitude of nonvoiding contractions in rats with spinal cord injury [Behr-Roussel et al. 2011]. In a study of bladder outlet obstruction through partial urethral ligation in rats, vardenafil decreased nonvoiding contractions [Filippi et al. 2007].

In addition to the effects on afferent nerves in the bladder, a study of bladder overactivity via partial urethral obstruction in rats demonstrated that intrathecal sildenafil citrate administered at the level of the sacral spinal cord decreased both the frequency of micturition and bladder pressure [Fullhase et al. 2013].

Decreased SMC proliferation

The findings from several in vitro studies indicate that PDE5 inhibitors exert antiproliferative effects on human SMCs. Specifically, in a study of human prostatic SMCs obtained from men with BPH, PDE5 inhibition was demonstrated to inhibit lysophosphatidic acid induced increases in DNA replication by nearly 100% [Adolfsson et al. 2002]. More recently, a study of human bladder, prostatic and urethral SMCs, obtained from men who underwent suprapubic adenectomy for BPH, demonstrated that vardenafil significantly increased the antiproliferative effect (determined by cell counting) of the NO donor SNP [Fibbi et al. 2010].

In addition to these effects on SMCs, a study of human prostatic stromal cells demonstrated that vardenafil significantly attenuated transforming growth factor β1-induced fibroblast-to-myofibroblast transdifferentiation (determined by assessing SMC actin and insulin-like growth factor binding protein 3 mRNA and protein levels), an important underlying change in BPH [Zenzmaier et al. 2012]. Furthermore, the fibroblast-like morphology in transdifferentiated myofibroblasts was restored [Zenzmaier et al. 2012].

Summary

Several different pathophysiological changes in the bladder, prostate, supporting vasculature and nerve supply may lead to LUTS in men with BPH. The abundance of PDE5 isoenzymes in the lower urinary tract and the inhibition of PDE5 in these tissues, leading to increased cGMP, have been demonstrated to reduce SMC proliferation, relax SMCs, increase tissue oxygenation and modulate afferent nerve activity. The improvement of symptoms in patients with BPH-LUTS treated with tadalafil is most likely mediated by a combination of these effects.

Clinical efficacy and safety data

More than 3000 men with BPH-LUTS have participated in 11 large, randomized, placebo-controlled studies of tadalafil carried out globally [McVary et al. 2007; Roehrborn et al. 2008; Dmochowski et al. 2010; Kim et al. 2011; Porst et al. 2011; Egerdie et al. 2012; Goldfischer et al. 2012; Oelke et al. 2012; Takeda et al. 2012, 2014; Yokoyama et al. 2013]. Two long-term, open-label studies enrolled 394 Japanese [Takeda et al. 2012] and 428 North American [Donatucci et al. 2011] men. In addition, two large, randomized, placebo-controlled studies of tadalafil combination therapy with finasteride [Casabe et al. 2014] or α-blockers [Goldfischer et al. 2012] enrolled 346 and 158 men, respectively. Studies enrolling fewer than 50 patients to the tadalafil treatment arm are not included in this review.

Efficacy

To date, three 12-week, randomized, controlled studies [Takeda et al. 2012; Yokoyama et al. 2013; Takeda et al. 2014], a 12-week, randomized, controlled pilot study [Kim et al. 2011], and a 42-week, open-label, extension study [Takeda et al. 2012] have investigated the efficacy of tadalafil 5 mg once-daily as a treatment for BPH-LUTS in men from Asian countries. Four 12-week, randomized, controlled studies [Roehrborn et al. 2008; Porst et al. 2011; Egerdie et al. 2012; Oelke et al. 2012] and a 1-year, open-label, extension study [Donatucci et al. 2011] have investigated the efficacy of tadalafil 5 mg once-daily in men from non-Asian countries. These studies included men aged ⩾45 years with a 6-month history of BPH-LUTS, a total International Prostate Symptom Score (IPSS) ⩾13 and intermediate voiding obstruction as defined by maximum urinary flow (Qmax) of 4–15 ml/s. In all of these studies, the primary or coprimary outcome was the change from baseline to endpoint in total IPSS for tadalafil 5 mg compared with placebo. The IPSS [Barry et al. 1992; Homma et al. 2002] is widely accepted and recommended as the standard instrument for assessing BPH-LUTS worldwide [Homma et al. 2011; Oelke et al. 2013].

Asian studies

The 12-week, double-blind, randomized, placebo-controlled studies of tadalafil 5 mg once-daily in Japanese men [Takeda et al. 2012], Japanese, Korean and Taiwanese men [Yokoyama et al. 2013], and Japanese and Korean men [Takeda et al. 2014] consistently demonstrated greater improvement in the change from baseline to endpoint in total IPSS for tadalafil 5 mg compared with placebo (Figure 2A). The improvement was significantly greater (p < 0.05) in two of these studies [Yokoyama et al. 2013; Takeda et al. 2014], whereas in the third smaller study [Takeda et al. 2012], the magnitude of symptom improvement (IPSS) was numerically greater (p = 0.062) on primary analysis (analysis of covariance) and significantly greater (p < 0.05) on secondary analysis (mixed-effects models repeated measures). Of note, integrated analysis of data from these three studies demonstrated significantly greater improvement in total IPSS for tadalafil 5 mg compared with placebo (mean change from baseline to endpoint: placebo = −3.8, tadalafil = −5.3; p < 0.001 [Nishizawa et al. 2015]).

Figure 2.

Figure 2.

Open in a new tab

Change from baseline to endpoint in total IPSS after 12 weeks of treatment with placebo or tadalafil 5 mg in (A) Asian and (B) non-Asian randomized, controlled studies of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia; p values represent the tadalafil versus placebo comparison in each study.

aFull study.

bPilot study.

IPSS, International Prostate Symptom Score; n = number of randomized participants.

The randomized, controlled Asian studies also consistently demonstrated greater improvement in secondary efficacy measures, including the change from baseline to endpoint in IPSS storage and voiding subscores and IPSS QoL index, for tadalafil 5 mg compared with placebo (Table 1). The magnitude of improvement in the IPSS storage subscore was significantly greater (p < 0.05) in two studies [Yokoyama et al. 2013; Takeda et al. 2014] and numerically greater in one study [Takeda et al. 2012], whereas the magnitude of improvement in the IPSS voiding subscore and IPSS QoL index was significantly greater (p < 0.05) in all three studies [Takeda et al. 2012, 2014; Yokoyama et al. 2013].

Table 1.

Mean changes from baseline to endpoint in IPSS storage and voiding subscores, IPSS quality of life index, and maximum urinary flow rate in 12-week, double-blind, randomized, placebo-controlled clinical studies of tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Study Treatment n Mean change from baseline
IPSS storage subscore IPSS voiding subscore IPSS QoL index Qmax, ml/s
Asian studies
 Takeda et al. [2014 ] Placebo 304 −1.4 −3.1 −0.9 0.6‡
Tadalafil 306 −2.0* −4.0* −1.1* 1.2‡
 Yokoyama et al. [2013]$ Placebo 154 −1.1 −1.9 −0.5 2.1
Tadalafil 155 −1.7* −3.0* −0.8* 1.3
 Takeda et al. [2012]$ Placebo 140 −1.4 −2.4 −0.4 1.4
Tadalafil 140 −1.6 −3.3* −0.7* 0.6
 Kim et al. [2011] Placebo 51 −1.5 −2.7 −0.9 2.3
Tadalafil 51 −2.1 −3.7 −1.2 2.5
Non-Asian studies
 Roehrborn et al. [2008]§ Placebo 210 −1.0 −1.3 −0.5 1.2
Tadalafil 212 −1.9* −2.9* −0.9* 1.6
 Egerdie et al. [2012]$ Placebo 200 −1.6 −2.2 −0.8 1.2
Tadalafil 208 −2.5* −3.6* −1.0 1.7
 Oelke et al. [2012] Placebo 172 −1.6 −2.6 −1.0 1.2
Tadalafil 171 −2.2 −4.1* −1.3* 2.4*
 Porst et al. [2011] Placebo 164 −1.3 −2.3 −0.7 1.1
Tadalafil 161 −2.3* −3.3* −1.0* 1.6
Open in a new tab
*

p < 0.05 versus placebo

$

Tadalafil 2.5 mg was also tested in this study.

‡

Median change from baseline to endpoint.

§

Tadalafil 2.5, 10., and 20 mg were also tested in this study.

IPSS = International Prostate Symptom Score; n = number of randomized participants; Qmax = maximum urinary flow rate; QoL = quality of life.

In the two randomized, controlled Asian studies in which assessments were made [Yokoyama et al. 2013; Takeda et al. 2014], a greater proportion of participants treated with tadalafil had better or improved urinary symptoms compared with those treated with placebo, as assessed by both the Patient and Clinician Global Impression of Improvement instruments.

In all three randomized, controlled Asian studies [Takeda et al. 2012; Yokoyama et al. 2013; Takeda et al. 2014], changes from baseline in Qmax were not significantly different for tadalafil 5 mg compared with placebo (Table 1).

The findings of the initial 12-week, double-blind, randomized, placebo-controlled, small pilot study of tadalafil 5 mg once-daily in Korean men [Kim et al. 2011] are consistent with those of the other Asian studies, demonstrating numerically greater improvements in the change from baseline to endpoint in total IPSS, IPSS subscores and IPSS QoL index for tadalafil 5 mg compared with placebo (Figure 2; Table 1). As in the other Asian studies, the change from baseline in Qmax was small and not significantly different for tadalafil compared with placebo (Table 1). Integrated analysis of data from Korean men in the pilot study [Kim et al. 2011] and the two randomized, controlled trials [Yokoyama et al. 2013; Takeda et al. 2014] also demonstrated significantly greater improvements in the change from baseline to endpoint in total IPSS, IPSS subscores and IPSS QoL index for tadalafil 5 mg compared with placebo [Lee et al. 2014].

The open-label extension of the study of tadalafil 5 mg once-daily carried out in Japanese men (n = 394) [Takeda et al. 2012] demonstrated that improvements in total IPSS, IPSS subscores and IPSS QoL index at the end of the 12-week, double-blind, placebo-controlled phase were maintained with long-term treatment (for up to 42 weeks). Although the change in Qmax observed at the end of the double-blind phase was not significantly different for tadalafil 5 mg compared with placebo, Qmax persistently improved with long-term treatment.

To obtain further information on the efficacy of tadalafil in Asian men with BPH-LUTS (specifically, factors that may be considered when prescribing medication for BPH-LUTS in the clinical setting), subgroup analyses by age (<65 years or ⩾65 years), severity of BPH-LUTS at baseline (mild-to-moderate or severe), previous α-blocker therapy within 12 months (yes or no) and prostate volume (<median or ⩾median) were carried out.  The three Asian studies [Takeda et al. 2012, 2014; Yokoyama et al. 2013] and the integrated analyses of data from these studies demonstrated numerically greater improvements in the change from baseline to endpoint in total IPSS for tadalafil 5 mg compared with placebo regardless of age, BPH-LUTS severity, previous α-blocker therapy or prostate volume grouping [Nishizawa et al. 2015].

The integrated analyses also demonstrated a number of within subgroup differences regarding total IPSS [Nishizawa et al. 2015]. Specifically, the magnitude of improvement was significantly greater for participants aged <65 years compared with participants aged ⩾65 years, whereas symptom severity at the end of treatment was similar in both age categories. Participants who had severe BPH-LUTS at baseline demonstrated numerically greater improvement compared with participants who had mild-to-moderate BPH-LUTS at baseline. Participants who had not received previous α-blocker therapy within 12 months demonstrated numerically greater improvement compared with participants who had received previous α-blocker therapy. Finally, the magnitude of improvement in total IPSS was similar among participants, regardless of prostate volume.

Non-Asian studies

The efficacy findings of the randomized, controlled non-Asian studies are generally consistent with those of the randomized, controlled Asian studies (Figure 2a; Table 1). Integrated analysis of data from these non-Asian studies demonstrated significantly greater (p < 0.001) improvement in the change from baseline in total IPSS for tadalafil compared with placebo (placebo = -2.7, tadalafil = -5.0) [Porst et al. 2013]. Likewise, there was significantly greater (p < 0.001) improvement in the change from baseline in IPSS storage and voiding subscores and IPSS QoL index for tadalafil compared with placebo [Porst et al. 2013]. Interestingly, the integrated analysis also demonstrated a small, but significant (p = 0.003), improvement in the change from baseline in median Qmax for tadalafil compared with placebo [Roehrborn et al. 2014]. This significant improvement (versus lack of significance in most individual studies and the integrated analyses of Asian data) likely reflects greater statistical power (n = 752 in the non-Asian studies versus n = 601 in the Asian studies) to detect a small difference and is consistent with tadalafil exerting some effect on SMC relaxation in the prostate or bladder neck. The clinical relevance of such an effect on improvement in BPH-LUTS is unclear [Roehrborn et al. 2014].

Subgroup analysis of pooled data from the four non-Asian studies demonstrated significantly greater (p < 0.05) improvement in the change from baseline in total IPSS for tadalafil compared with placebo regardless of baseline age (<65 years versus ⩾65 years), severity of BPH-LUTS, previous α-blocker use within 12 months, or prostate-specific antigen-predicted prostate volume [Porst et al. 2013].

Integrated analysis [Oelke et al. 2014] of data from the four non-Asian studies demonstrated a small but significant (p = 0.002) improvement in the change from baseline to endpoint in the severity of nocturia (IPSS question 7) for tadalafil 5 mg compared with placebo. However, the treatment difference (–0.2) was not considered to be clinically meaningful.

Integrated analyses [Brock et al. 2013, 2014] of data from non-Asian studies have also demonstrated that ED does not affect the LUTS treatment response to tadalafil in men with BPH-LUTS. The impact of ED on the efficacy and safety of tadalafil 5 mg was investigated in an integrated analysis [Brock et al. 2013] of data, which included men with BPH-LUTS who had ED and men with BPH-LUTS who did not have ED, from three of the non-Asian studies [Roehrborn et al. 2008; Porst et al. 2011; Oelke et al. 2012]. Significantly greater (p < 0.05) improvements in the change from baseline in total IPSS, IPSS subscores and IPSS QoL index for tadalafil compared with placebo were found, regardless of ED status (treatment-by-ED-status interaction: all p ⩾ 0.687).

More recently, an integrated analysis [Brock et al. 2014] of data from all four non-Asian studies [Roehrborn et al. 2008; Porst et al. 2011; Egerdie et al. 2012; Oelke et al. 2012] assessed whether the effects of treatment with tadalafil 5 mg for BPH-LUTS were independent of improvements in ED. A weak correlation (r2 = 0.08) between the change from baseline in total IPSS and the change from baseline in the International Index of Erectile Function-Erectile Function (IIEF-EF) domain score was detected. Further, unidirectional path analysis revealed that 70% of the improvement in total IPSS was due to a direct effect of tadalafil, whereas 30% of the improvement in total IPSS was due to an indirect effect of tadalafil via improvement in IIEF-EF (p < 0.001). Bidirectional path analysis revealed that 92.5% of the improvement in total IPSS was due to a direct effect of tadalafil, whereas 7.5% of the improvement in total IPSS was due to an indirect effect of tadalafil via improvement in IIEF-EF (p < 0.001). These findings indicate that tadalafil exerts independent effects on BPH-LUTS and ED.

Comparison of efficacy with tamsulosin

There are very limited publically available data from 12-week, double-blind, randomized, placebo-controlled studies of tamsulosin in Asian men with BPH-LUTS (Table 2). The available data, mostly from clinical tadalafil studies [Kim et al. 2011; Yokoyama et al. 2013], demonstrate placebo-adjusted improvement in the change from baseline in total IPSS after treatment with tamsulosin 0.2 mg once-daily ranging from −1.2 to −2.5. In comparison, the placebo-adjusted improvement with tadalafil 5 mg once-daily ranged from −1.1 to −1.7 in the Asian studies [Kim et al. 2011; Takeda et al. 2012; Yokoyama et al. 2013; Takeda et al. 2014] (and from −1.9 to −2.6 in the non-Asian studies [Roehrborn et al. 2008; Porst et al. 2011; Egerdie et al. 2012; Oelke et al. 2012]). Placebo-adjusted improvements in IPSS subscores and IPSS QoL index were also generally similar for tamsulosin 0.2 mg and tadalafil 5 mg in the Asian studies. Changes from baseline in Qmax were generally small in the placebo-controlled studies of tamsulosin and the Asian studies of tadalafil. Although Qmax has historically been a commonly reported measure in studies examining medical therapies for BPH-LUTS, it is worth noting that both the American Urological Association guideline for the management of BPH and the JUA BPH guidelines indicate that increases in Qmax are poorly correlated with symptomatic improvement [American Urological Association Practice Guidelines Committee, 2010; Homma et al. 2011]

Table 2.

Mean changes from baseline to end point in total IPSS, IPSS subscores, IPSS quality of life index, and maximum flow rate in 12-week, double-blind, randomized, placebo-controlled clinical studies of tamsulosin in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Study Treatment n Mean change from baseline
Total IPSS IPSS storage subscore IPSS voiding subscore IPSS QoL index Qmax, ml/s
Asian studies$
 Yokoyama et al. [2013] Placebo 154 −3.0 −1.1 −1.9 −0.5 2.1
Tadalafil 5 mg 155 −4.7* −1.7* −3.0* −0.8* 1.3
Tamsulosin 0.2 mg 152 −5.5 −1.7 −3.8 −1.1 2.1
 Kawabe et al. [2006] Placebo 89 −5.3 −1.5 −3.8 −1.1 0.3
Tamsulosin 0.2 mg 192 −6.8 −2.1 −4.8 −1.4 2.6
 Kim et al. [2011] Placebo 51 −4.2 −1.5 −2.7 −0.9 2.3
Tadalafil 5 mg 51 −5.8 −2.1 −3.7 −1.2 2.5
Tamsulosin 0.2 mg 49 −5.4 −1.8 −3.6 −1.0 2.1
Non-Asian study
 Oelke et al. [2012] Placebo 172 −4.2 −1.6 −2.6 −1.0 1.2
Tadalafil 5 mg 171 −6.3* −2.2 −4.1* −1.3* 2.4*
Tamsulosin 0.4 mg 168 −5.7* −2.2 −3.5* −1.1 2.2*
Open in a new tab
*

p < 0.05 versus placebo.

$

Tamsulosin versus placebo statistical comparisons were not made in the studies reported by Kawabe et al. [2006] and Yokoyama et al. [2013].

IPSS, International Prostate Symptom Score; n, number of randomized participants; Qmax, maximum urinary flow rate; QoL, quality of life.

The available data from Asian studies of men with BPH-LUTS suggest that tadalafil 5 mg once-daily for 12 weeks results in improvements in total IPSS, IPSS subscores and IPSS QoL index that are generally similar to those observed with tamsulosin 0.2 mg once-daily. In comparison, a 12-week, double-blind, randomized, placebo-controlled, non-Asian study of tadalafil 5 mg or tamsulosin 0.4 mg once-daily in men with BPH-LUTS [Oelke et al. 2012] demonstrated a placebo-adjusted improvement in the change from baseline in total IPSS of −2.1 for tadalafil 5 mg and −1.5 for tamsulosin 0.4 mg (Table 2).

Summary

The 12-week Asian studies demonstrated consistently greater improvements in the change from baseline in total IPSS, IPSS subscores and IPSS QoL index for tadalafil 5 mg compared with placebo in men with BPH-LUTS. The improvements at 12 weeks were maintained for 42 weeks, demonstrating the long-term efficacy of tadalafil 5 mg. Furthermore, the greater improvements were apparent regardless of age, severity of BPH-LUTS, previous α-blocker therapy, or prostate volume subgroupings. These findings are consistent with the efficacy findings from the non-Asian studies of tadalafil 5 mg once-daily in men BPH-LUTS and demonstrate that tadalafil 5 mg once-daily is an efficacious treatment for Asian men with BPH-LUTS.

Safety

To date, three randomized, controlled studies [Takeda et al. 2012, 2014; Yokoyama et al. 2013], a randomized, controlled pilot study [Kim et al. 2011, and an open-label extension study [Takeda et al. 2012] have investigated the safety and tolerability of tadalafil 5 mg once-daily as a treatment for BPH-LUTS in men from Asian countries, whereas four randomized, controlled studies have investigated the safety and tolerability of tadalafil 5 mg in men from non-Asian countries [Roehrborn et al. 2008; Porst et al. 2011; Egerdie et al. 2012; Oelke et al. 2012]. A randomized, controlled study has also investigated the urodynamic safety of tadalafil 20 mg once-daily in men from non-Asian countries [Dmochowski et al. 2010].

Asian studies

Tadalafil 5 mg was well tolerated in the randomized, controlled Asian studies [Takeda et al. 2012, 2014; Yokoyama et al. 2013] and had a safety profile consistent with the known safety profile of tadalafil as per the current package insert for tadalafil (Cialis) 5 mg to 20 mg as needed for ED [Eli Lilly Japan, 2012]. Integrated analysis of safety data from these studies demonstrated that the most common treatment-emergent adverse events (TEAEs) were nasopharyngitis, dyspepsia and headache (Table 3). Few participants experienced serious adverse events (placebo = 0.5%, tadalafil = 0.7%; none were considered to be treatment-related) or TEAEs leading to discontinuation (placebo = 2.7%, tadalafil = 1.8%).

Table 3.

Treatment-emergent adverse events reported by ⩾2% of participants in 12-week, double-blind, randomized, placebo-controlled clinical studies of tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Common TEAEs Asian studies*
 Non-Asian studies$
Placebo (n = 598) Tadalafil 5 mg(n = 601) Placebo (n = 748) Tadalafil 5 mg (n = 752)
Dyspepsia 0.3% 3.0% 0.1% 2.4%
Headache 1.7% 2.5% 2.0% 3.9%
Nasopharyngitis 5.4% 4.8% 2.3% 2.3%
Open in a new tab
*

Safety dataset pooled from all participants in the Asian studies [Takeda et al. 2012, 2014; Yokoyama et al. 2013].

$

Safety dataset pooled from all participants in the non-Asian studies [Roehrborn et al. 2008; Porst et al. 2011; Egerdie et al. 2012; Oelke et al. 2012].

n, number of randomized participants; TEAEs, treatment-emergent adverse events.

The type and frequency of individual TEAEs in the pilot study [Kim et al. 2011] were similar to those reported in the randomized, controlled Asian studies. No new or unexpected safety findings were observed with longer term treatment [Takeda et al. 2012].

Subgroup analysis of data from the three randomized, controlled Asian studies demonstrated that there were no meaningful differences in safety findings by age, ethnicity, pre-existing disease, renal function, or previous α-blocker therapy [unpublished data].

Non-Asian studies

The safety and tolerability findings of the non-Asian studies are consistent with those of the Asian studies. Integrated analysis of data from the non-Asian studies of tadalafil 5 mg demonstrated that the most common TEAEs were headache, back pain (placebo = 1.2%, tadalafil = 2.4%), dyspepsia and nasopharyngitis (Table 3). As in the Asian studies, few participants experienced serious adverse events (placebo = 0.7%, tadalafil = 0.8%) or TEAEs leading to discontinuation (placebo = 1.5%, tadalafil = 3.1%).

The findings from the double-blind, placebo-controlled, 12-week, invasive/noninvasive urodynamic study [Dmochowski et al. 2010] of tadalafil 20 mg in men with BPH-LUTS (with and without bladder outlet obstruction) indicate that tadalafil has no negative effects on bladder function. In this study, there were no statistically significant or clinically adverse differences between tadalafil and placebo in change in detrusor pressure at Qmax, mean urine flow, voided volume, maximum detrusor pressure during voiding, postvoid residual volume, total bladder capacity, bladder voiding efficiency, bladder contractility index, bladder outlet obstruction index, presence of involuntary detrusor contractions during bladder filling, or bladder volume at first involuntary detrusor contraction. As participants with detrusor overactivity were not excluded or proactively enrolled and the frequency or amplitude of detrusor contractions were not assessed, no conclusions can be made from the results of this study regarding the effects of tadalafil on detrusor overactivity.

Summary

Tadalafil was well tolerated and no new safety concerns were identified in any of the Asian studies. The safety findings from the non-Asian studies of tadalafil 5 mg once-daily in men with BPH-LUTS are consistent with the corresponding findings from the Asian studies.

Tadalafil combination therapy

Tadalafil/α-blocker combination therapy

No large, double-blind, placebo-controlled study has assessed the efficacy of tadalafil/α-blocker combination therapy. However, several small clinical studies have reported that tadalafil/α-blocker combination therapy may provide greater improvement in the change from baseline in total IPSS than α-blocker therapy alone [Bechara et al. 2008; Liguori et al. 2009] or tadalafil therapy alone [Liguori et al. 2009; Singh et al. 2014] in men with BPH-LUTS. However, these studies either included a small number of participants, involved tadalafil doses >5 mg once-daily, and/or were not placebo controlled.

The safety of tadalafil 5 mg in combination with α-blockers (alfuzosin, silodosin, tamsulosin, doxazosin or terazosin) was investigated in a US double-blind, randomized, placebo-controlled trial of men with BPH-LUTS (tadalafil/α-blocker, n = 158; placebo, n = 160) [Goldfischer et al. 2012]. This study was not designed to assess efficacy. No new safety concerns were identified for tadalafil/α-blocker combination therapy in this study. Furthermore, the proportion of participants reporting treatment-emergent dizziness or with a positive orthostatic test was similar between the tadalafil/α-blocker combination therapy group and the placebo/α-blocker combination therapy group.

Note that combining doxazosin with tadalafil is not recommended (per the package inserts for Cialis and Zalutia) as tadalafil may potentiate the hypotensive effects of this non-uroselective α-blocker [Kloner et al. 2004; Guillaume et al. 2007; Eli Lilly Japan, 2014].

Tadalafil/5ARI combination therapy

Several clinical studies have examined the efficacy and safety of tadalafil/5ARI combination therapy, with simultaneous initiation, in men with an enlarged prostate and BPH-LUTS. In a multinational, randomized, double-blind, 26-week study of finasteride 5 mg/tadalafil 5 mg (n = 346) compared with finasteride 5 mg/placebo (n = 350) [Roehrborn et al. 2015; Casabe et al. 2014; Glina et al. 2014], there was significantly greater (p < 0.05) improvement in the change from baseline in total IPSS for finasteride/tadalafil compared with finasteride/placebo at weeks 4, 12 and 26 [Casabe et al. 2014]. There were also significant treatment differences in secondary outcomes assessed, including the change from baseline in the IPSS voiding subscore for finasteride/tadalafil compared with finasteride/placebo at weeks 4, 12, and 26, the IPSS storage subscore at weeks 4 and 12 and IPSS QoL index at week 4. Furthermore, participants who received finasteride/tadalafil were significantly more satisfied with their treatment (Treatment Satisfaction Scale-BPH) at week 26 than participants who received finasteride/placebo [Roehrborn et al. 2015]. In a small, 12-week, Korean, randomized study, a similar magnitude of improvement in the change from baseline in total IPSS at week 12 was found for tadalafil 5 mg/dutasteride 0.5 mg (−2.3, n = 86) compared with tamsulosin 0.2 mg/dutasteride 0.5 mg (−2.5, n = 82) [Park and Park, 2013].

No new safety concerns were identified for tadalafil/5ARI combination therapy in either of these studies [Park and Park, 2013; Casabe et al. 2014]. In the 26-week study, a lower proportion of participants who received finasteride/tadalafil discontinued compared with participants who received finasteride/placebo [Casabe et al. 2014]. Few participants in either group reported adverse events related to sexual dysfunction [Glina et al. 2014].

The findings from these studies suggest that tadalafil/5ARI combination therapy may result in earlier and greater improvement in BPH-LUTS compared with 5ARI therapy alone [Casabe et al. 2014] and that tadalafil/dutasteride combination therapy may result in similar improvements in BPH-LUTS compared with tamsulosin/dutasteride combination therapy [Park and Park, 2013].

Summary

The available data from large, well-controlled studies suggest that tadalafil/5ARI combination therapy provides added benefit in the treatment of BPH-LUTS compared with 5ARI monotherapy and that both tadalafil/α-blocker and tadalafil/5ARI combination therapy have favorable safety profiles.

Conclusion

Studies have shown that the inhibition of PDE5 isoenzymes relaxes smooth muscle in the prostate and bladder neck (via cGMP), increases blood perfusion to the prostate and bladder, and decreases bladder afferent nerve activity. These underlying effects of tadalafil are in keeping with the findings from clinical studies, which have demonstrated that tadalafil relieves BPH-LUTS. Specifically, clinical studies carried out in Asian and non-Asian countries have demonstrated that tadalafil 5 mg once-daily is an efficacious treatment for men with BPH-LUTS and has a safety profile consistent with the known safety profile of tadalafil for ED. These findings support tadalafil monotherapy for men, including Asian men, with BPH-LUTS. Clinical studies also suggest that tadalafil/5ARI combination therapy may be more efficacious than 5ARI monotherapy, and that tadalafil/5ARI and tadalafil/uroselective α-blocker combination therapy have favorable safety profiles.

Acknowledgments

We thank Yukiko Inoue for editorial support.

Footnotes

Funding: Medical writing assistance was provided by Luke Carey, PhD, and Serina Stretton, PhD, CMPP, of ProScribe – part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. (Eli Lilly and Company is the manufacturer of tadalafil). ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2).

Conflict of interest statement: T.Y. and M.M. are employees of Eli Lilly Japan K.K. L.V. is an employee of Eli Lilly and Company. O.Y., Y.I. and M.T. have been advisory board members for Eli Lilly Japan K.K. M.M. and L.V. are stockholders of Eli Lilly and Company.

Contributor Information

Osamu Yokoyama, Department of Urology, Faculty of Medical Science, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan.

Yasuhiko Igawa, Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Masayuki Takeda, Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan.

Takafumi Yamaguchi, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Hyogo, Japan.

Masahiro Murakami, Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Hyogo, Japan.

Lars Viktrup, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, USA.

References

  1. Abdelwahab O., El-Barky E., Khalil M., Kamar A. (2012) Evaluation of the resistive index of prostatic blood flow in benign prostatic hyperplasia. Int Braz J Urol 38: 250–255; discussion 255–257. [DOI] [PubMed] [Google Scholar]
  2. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 37–49. [DOI] [PubMed] [Google Scholar]
  3. Adolfsson P., Ahlstrand C., Varenhorst E., Svensson S. (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50–58. [DOI] [PubMed] [Google Scholar]
  4. American Urological Association Practice Guidelines Committee (2010) American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association; Available at: https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm (accessed 23 June 2014). [Google Scholar]
  5. Andersson K., De Groat W., McVary K., Lue T., Maggi M., Roehrborn C., et al. (2011) Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 30: 292–301. [DOI] [PubMed] [Google Scholar]
  6. Angulo J., Cuevas P., Fernandez A., La Fuente J., Allona A., Moncada I., et al. (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9: 2293–2306. [DOI] [PubMed] [Google Scholar]
  7. Barry M., Fowler F., Jr., O’Leary M., Bruskewitz R., Holtgrewe H., Mebust W., et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549–1557. [DOI] [PubMed] [Google Scholar]
  8. Bechara A., Romano S., Casabe A., Haime S., Dedola P., Hernandez C., et al. (2008) Comparative efficacy assessment of tamsulosin versus. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5: 2170–2178. [DOI] [PubMed] [Google Scholar]
  9. Behr-Roussel D., Oger S., Caisey S., Sandner P., Bernabe J., Alexandre L., et al. (2011) Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 59: 272–279. [DOI] [PubMed] [Google Scholar]
  10. Berger A., Deibl M., Leonhartsberger N., Bektic J., Horninger W., Fritsche G., et al. (2005) Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96: 1073–1078. [DOI] [PubMed] [Google Scholar]
  11. Bertolotto M., Trincia E., Zappetti R., Bernich R., Savoca G., Cova M. (2009) Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med 114: 1106–1114. [DOI] [PubMed] [Google Scholar]
  12. Bittencourt J., Tano T., Gajar S., Resende A., De Lemos Neto M., Damiao R., et al. (2009) Relaxant effects of sildenafil on the human isolated bladder neck. Urology 73: 427–430. [DOI] [PubMed] [Google Scholar]
  13. Brock G., Broderick G., Roehrborn C., Xu L., Wong D., Viktrup L. (2013) Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU Int 112: 990–997. [DOI] [PubMed] [Google Scholar]
  14. Brock G., McVary K., Roehrborn C., Watts S., Ni X., Viktrup L., et al. (2014) Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 191: 405–411. [DOI] [PubMed] [Google Scholar]
  15. Casabe A., Roehrborn C., Da Pozzo L., Zepeda S., Henderson R., Sorsaburu S., et al. (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191: 727–733. [DOI] [PubMed] [Google Scholar]
  16. Cortijo J., Naline E., Ortiz J., Berto L., Girard V., Malbezin M., et al. (1998) Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study. Eur J Pharmacol 341: 79–86. [DOI] [PubMed] [Google Scholar]
  17. Coyne K., Sexton C., Thompson C., Milsom I., Irwin D., Kopp Z., et al. (2009) The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 104: 352–360. [DOI] [PubMed] [Google Scholar]
  18. De Nunzio C., Aronson W., Freedland S., Giovannucci E., Parsons J. (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61: 560–570. [DOI] [PubMed] [Google Scholar]
  19. Dmochowski R., Roehrborn C., Klise S., Xu L., Kaminetsky J., Kraus S. (2010) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 183: 1092–1097. [DOI] [PubMed] [Google Scholar]
  20. Donatucci C., Brock G., Goldfischer E., Pommerville P., Elion-Mboussa A., Kissel J., et al. (2011) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 107: 1110–1116. [DOI] [PubMed] [Google Scholar]
  21. Egerdie R., Auerbach S., Roehrborn C., Costa P., Garza M., Esler A., et al. (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9: 271–281. [DOI] [PubMed] [Google Scholar]
  22. Eli Lilly Japan (2012) Cialis. Package insert. Kobe, Japan: Eli Lilly Japan K.K. [Google Scholar]
  23. Eli Lilly Japan (2014) Zalutia. Package insert. Kobe, Japan: Eli Lilly Japan K.K. [Google Scholar]
  24. Fibbi B., Morelli A., Vignozzi L., Filippi S., Chavalmane A., De Vita G., et al. (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7: 59–69. [DOI] [PubMed] [Google Scholar]
  25. Filippi S., Morelli A., Sandner P., Fibbi B., Mancina R., Marini M., et al. (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148: 1019–1029. [DOI] [PubMed] [Google Scholar]
  26. Francis S., Busch J., Corbin J., Sibley D. (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62: 525–563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Fullhase C., Hennenberg M., Giese A., Schmidt M., Strittmatter F., Soler R., et al. (2013) Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol 190: 1430–1435. [DOI] [PubMed] [Google Scholar]
  28. Gacci M., Corona G., Vignozzi L., Salvi M., Serni S., De Nunzio C., et al. (2015) Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 115: 24–31. [DOI] [PubMed] [Google Scholar]
  29. Giuliano F., Uckert S., Maggi M., Birder L., Kissel J., Viktrup L. (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63: 506–516. [DOI] [PubMed] [Google Scholar]
  30. Glina S., Roehrborn C., Esen A., Plekhanov A., Sorsaburu S., Henneges C., et al. (2014) Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil co-administered with finasteride. J Sex Med 12: 129–138. [DOI] [PubMed] [Google Scholar]
  31. Goldfischer E., Kowalczyk J., Clark W., Brady E., Shane M., Dgetluck N., et al. (2012) Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant alpha1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. Urology 79: 875–882. [DOI] [PubMed] [Google Scholar]
  32. Guillaume M., Lonsdale F., Darstein C., Jimenez M., Mitchell M. (2007) Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha- adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. J Clin Pharmacol 47: 1303–1310. [DOI] [PubMed] [Google Scholar]
  33. Haaga J., Exner A., Fei B., Seftel A. (2007) Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res 19: 110–113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Haslam R., Dickinson N., Jang E. (1999) Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 82: 412–423. [PubMed] [Google Scholar]
  35. Homma Y., Gotoh M., Yokoyama O., Masumori N., Kawauchi A., Yamanishi T., et al. (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 18: 741–756. [DOI] [PubMed] [Google Scholar]
  36. Homma Y., Tsukamoto T., Yasuda K., Ozono S., Yoshida M., Shinji M. (2002) Linguistic validation of Japanese version of International Prostate Symptom Score and BPH impact index. Nippon Hinyokika Gakkai Zasshi 93: 669–680. [DOI] [PubMed] [Google Scholar]
  37. Irwin D., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1314; discussion 1314–1305. [DOI] [PubMed] [Google Scholar]
  38. Jacobsen S., Guess H., Panser L., Girman C., Chute C., Oesterling J., et al. (1993) A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 2: 729–735. [DOI] [PubMed] [Google Scholar]
  39. Kang J., Min G., Son H., Kim H., Lee H. (2011) National-wide data on the treatment of BPH in Korea. Prostate Cancer Prostatic Dis 14: 243–247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kawabe K., Yoshida M., Homma Y. (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019–1024. [DOI] [PubMed] [Google Scholar]
  41. Kim S., Park J., Kim S., Lee S., Ahn T., Kim J., et al. (2011) Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. LUTS 3: 86–93. [DOI] [PubMed] [Google Scholar]
  42. Kloner R., Jackson G., Emmick J., Mitchell M., Bedding A., Warner M., et al. (2004) Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172: 1935–1940. [DOI] [PubMed] [Google Scholar]
  43. Kojima M., Watanabe H., Watanabe M., Okihara K., Naya Y., Ukimura O. (1997) Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 23: 1305–1309. [DOI] [PubMed] [Google Scholar]
  44. Kotera J., Fujishige K., Omori K. (2000) Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48: 685–693. [DOI] [PubMed] [Google Scholar]
  45. Lee E., Yoo K., Kim Y., Shin Y., Lee C. (1998) Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 33: 17–21. [DOI] [PubMed] [Google Scholar]
  46. Lee S., Paick J., Park H., Won J., Morisaki Y., Sorsaburu S., et al. (2014) The efficacy and safety of tadalafil 5 mg once daily in Korean men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: an integrated analysis. World J Mens Health 32: 28–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Li M., Garcia L., Rosen R. (2005) Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 96: 1339–1354. [DOI] [PubMed] [Google Scholar]
  48. Liguori G., Trombetta C., De Giorgi G., Pomara G., Maio G., Vecchio D., et al. (2009) Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 6: 544–552. [DOI] [PubMed] [Google Scholar]
  49. Loughney K., Hill T., Florio V., Uher L., Rosman G., Wolda S., et al. (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216: 139–147. [DOI] [PubMed] [Google Scholar]
  50. Mammi C., Pastore D., Lombardo M., Ferrelli F., Caprio M., Consoli C., et al. (2011) Sildenafil reduces insulin-resistance in human endothelial cells. PLoS One 6: e14542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. McVary K., Roehrborn C., Kaminetsky J., Auerbach S., Wachs B., Young J., et al. (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401–1407. [DOI] [PubMed] [Google Scholar]
  52. Minagawa T., Aizawa N., Igawa Y., Wyndaele J. (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 110: E259–E266. [DOI] [PubMed] [Google Scholar]
  53. Morelli A., Filippi S., Comeglio P., Sarchielli E., Chavalmane A., Vignozzi L., et al. (2010) Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 7: 107–120. [DOI] [PubMed] [Google Scholar]
  54. Morelli A., Sarchielli E., Comeglio P., Filippi S., Mancina R., Gacci M., et al. (2011a) Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 8: 2746–2760. [DOI] [PubMed] [Google Scholar]
  55. Morelli G., Pagni R., Mariani C., Minervini R., Morelli A., Gori F., et al. (2011b) Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer. J Urol 185: 2126–2131. [DOI] [PubMed] [Google Scholar]
  56. Moul S., McVary K. (2010) Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 20: 7–12. [DOI] [PubMed] [Google Scholar]
  57. Musicki B., Bivalacqua T., Champion H., Burnett A. (2014) Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis. J Sex Med 11: 424–430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Nishizawa O., Yoshida M., Takeda M., Yokoyama O., Morisaki Y., Murakami M., et al. (2015) Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. Int J Urol 22: 378–384. [DOI] [PubMed] [Google Scholar]
  59. Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M., et al. (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64: 118–140. [DOI] [PubMed] [Google Scholar]
  60. Oelke M., Giuliano F., Mirone V., Xu L., Cox D., Viktrup L. (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61: 917–925. [DOI] [PubMed] [Google Scholar]
  61. Oelke M., Weiss J., Mamoulakis C., Cox D., Ruff D., Viktrup L. (2014) Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World J Urol 32: 1127–1132. [DOI] [PubMed] [Google Scholar]
  62. Ozden C., Gunay I., Deren T., Bulut S., Ozdal O., Koparal S., et al. (2010) Effect of transurethral resection of prostate on prostatic resistive index. Urol Int 84: 191–193. [DOI] [PubMed] [Google Scholar]
  63. Park H., Park N. (2013) Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasia. Eur Urol 12(Suppl): e1092. [Google Scholar]
  64. Pinggera G., Frauscher F., Paduch D., Bolyakov A., Efros M., Kaminetsky J., et al. (2014) Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomized, double-blind, multicenter, placebo-controlled trial. Urology 84: 412–420. [DOI] [PubMed] [Google Scholar]
  65. Porst H., Kim E., Casabe A., Mirone V., Secrest R., Xu L., et al. (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60: 1105–1113. [DOI] [PubMed] [Google Scholar]
  66. Porst H., Oelke M., Goldfischer E., Cox D., Watts S., Dey D., et al. (2013) Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 82: 667–673. [DOI] [PubMed] [Google Scholar]
  67. Roehrborn C. (2008) Pathology of benign prostatic hyperplasia. Int J Impot Res 20(Suppl. 3): S11–S18. [DOI] [PubMed] [Google Scholar]
  68. Roehrborn C., Casabe A., Glina S., Sorsaburu S., Henneges C., Viktrup L. (2015) Treatment satisfaction and clinically meaningful improvement with tadalafil and finasteride coadministration in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int J Urol. DOI: 10.1111/iju.12741. [DOI] [PubMed] [Google Scholar]
  69. Roehrborn C., Chapple C., Oelke M., Cox D., Esler A., Viktrup L. (2014) Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol 191: 1045–1050. [DOI] [PubMed] [Google Scholar]
  70. Roehrborn C., McVary K., Elion-Mboussa A., Viktrup L. (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228–1234. [DOI] [PubMed] [Google Scholar]
  71. Rosano G., Aversa A., Vitale C., Fabbri A., Fini M., Spera G. (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47: 214–220. [DOI] [PubMed] [Google Scholar]
  72. Rosen R., Altwein J., Boyle P., Kirby R., Lukacs B., Meuleman E., et al. (2003) Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 44: 637–649. [DOI] [PubMed] [Google Scholar]
  73. Rybalkin S., Bornfeldt K. (1999) Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82: 424–434. [PubMed] [Google Scholar]
  74. Singh D., Mete U., Mandal A., Singh S. (2014) A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil versus. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 11: 187–196. [DOI] [PubMed] [Google Scholar]
  75. Taher A., Meyer M., Stief C., Jonas U., Forssmann W. (1997) Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 15: 32–35. [DOI] [PubMed] [Google Scholar]
  76. Takeda M., Nishizawa O., Imaoka T., Maikuma H., Morisaki Y., Viktrup L. (2012) Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12-week placebo-controlled dose-finding study with a 42-week open-label extension LUTS 4: 110–119. [DOI] [PubMed] [Google Scholar]
  77. Takeda M., Tang R., Shapiro E., Burnett A., Lepor H. (1995) Effects of nitric oxide on human and canine prostates. Urology 45: 440–446. [DOI] [PubMed] [Google Scholar]
  78. Takeda M., Yokoyama O., Lee S., Murakami M., Morisaki Y., Viktrup L. (2014) Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol 21: 670–675. [DOI] [PubMed] [Google Scholar]
  79. Terai A., Kakehi Y., Terachi T., Ogawa O. (2000) National trend of management of benign prostatic hyperplasia in Japan during 1990s: analysis of national health statistics. Hinyokika Kiyo 46: 537–544. [PubMed] [Google Scholar]
  80. Traish A., Hassani J., Guay A., Zitzmann M., Hansen M. (2011) Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 8: 872–884. [DOI] [PubMed] [Google Scholar]
  81. Tsukamoto T., Kumamoto Y., Masumori N., Miyake H., Rhodes T., Girman C., et al. (1995) Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 154: 391–395. [DOI] [PubMed] [Google Scholar]
  82. Tsuru N., Kurita Y., Masuda H., Suzuki K., Fujita K. (2002) Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 9: 427–430. [DOI] [PubMed] [Google Scholar]
  83. Uckert S., Kuthe A., Jonas U., Stief C. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484–2490. [PubMed] [Google Scholar]
  84. Uckert S., Sormes M., Kedia G., Scheller F., Knapp W., Jonas U., et al. (2008) Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71: 526–530. [DOI] [PubMed] [Google Scholar]
  85. Verhamme K., Dieleman J., Bleumink G., Van Der Lei J., Sturkenboom M., Artibani W., et al. (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur Urol 42: 323–328. [DOI] [PubMed] [Google Scholar]
  86. Waldkirch E., Uckert S., Langnase K., Richter K., Jonas U., Wolf G., et al. (2007) Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 52: 495–501. [DOI] [PubMed] [Google Scholar]
  87. Watkins C., Sawa A., Jaffrey S., Blackshaw S., Barrow R., Snyder S., et al. (2000) Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 106: 373–384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Wei J., Calhoun E., Jacobsen S. (2008) Urologic diseases in america project: benign prostatic hyperplasia. J Urol 179: S75–S80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Werkstrom V., Svensson A., Andersson K., Hedlund P. (2006) Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 98: 414–423. [DOI] [PubMed] [Google Scholar]
  90. Yokoyama O., Yoshida M., Kim S., Wang C., Imaoka T., Morisaki Y., et al. (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 20: 193–201. [DOI] [PubMed] [Google Scholar]
  91. Zenzmaier C., Kern J., Sampson N., Heitz M., Plas E., Untergasser G., et al. (2012) Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology 153: 5546–5555. [DOI] [PubMed] [Google Scholar]
  92. Zhang X., Li G., Wei X., Mo X., Hu L., Zha Y., et al. (2012) Resistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol 188: 881–887. [DOI] [PubMed] [Google Scholar]

Articles from Therapeutic Advances in Urology are provided here courtesy of SAGE Publications

RESOURCES